Baker BROS. Advisors LP Sells 952,658 Shares of Structure Therapeutics Inc. Sponsored ADR $GPCR

Baker BROS. Advisors LP decreased its position in Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) by 38.0% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,556,109 shares of the company’s stock after selling 952,658 shares during the quarter. Baker BROS. Advisors LP owned approximately 2.70% of Structure Therapeutics worth $43,571,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in GPCR. Balyasny Asset Management L.P. bought a new position in shares of Structure Therapeutics during the third quarter valued at about $12,923,000. Orbimed Advisors LLC grew its position in Structure Therapeutics by 49.5% in the 2nd quarter. Orbimed Advisors LLC now owns 1,199,300 shares of the company’s stock worth $24,873,000 after purchasing an additional 397,272 shares in the last quarter. Pacific Heights Asset Management LLC grew its position in Structure Therapeutics by 52.2% in the 3rd quarter. Pacific Heights Asset Management LLC now owns 700,000 shares of the company’s stock worth $19,600,000 after purchasing an additional 240,000 shares in the last quarter. Aberdeen Group plc increased its stake in Structure Therapeutics by 46.1% in the 3rd quarter. Aberdeen Group plc now owns 586,869 shares of the company’s stock valued at $16,432,000 after buying an additional 185,245 shares during the last quarter. Finally, Two Sigma Investments LP bought a new position in shares of Structure Therapeutics during the 3rd quarter worth approximately $5,122,000. Hedge funds and other institutional investors own 91.78% of the company’s stock.

Structure Therapeutics Stock Down 1.5%

Shares of GPCR stock opened at $53.75 on Friday. The firm has a market cap of $3.81 billion, a P/E ratio of -68.04 and a beta of -1.80. The company has a 50 day moving average of $73.46 and a 200-day moving average of $49.50. Structure Therapeutics Inc. Sponsored ADR has a 12-month low of $13.22 and a 12-month high of $94.90.

Structure Therapeutics (NASDAQ:GPCR) last posted its quarterly earnings data on Thursday, February 26th. The company reported ($0.49) EPS for the quarter, missing the consensus estimate of ($0.35) by ($0.14). As a group, equities analysts expect that Structure Therapeutics Inc. Sponsored ADR will post -0.82 EPS for the current year.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on GPCR. JPMorgan Chase & Co. upped their target price on Structure Therapeutics from $65.00 to $105.00 and gave the company an “overweight” rating in a report on Thursday, January 22nd. Weiss Ratings reiterated a “sell (d-)” rating on shares of Structure Therapeutics in a report on Thursday, January 22nd. Citigroup reissued an “outperform” rating on shares of Structure Therapeutics in a research report on Friday, December 12th. Jefferies Financial Group set a $125.00 price objective on Structure Therapeutics and gave the company a “buy” rating in a research note on Thursday, December 11th. Finally, The Goldman Sachs Group raised Structure Therapeutics to a “strong-buy” rating in a research report on Tuesday, January 20th. Two research analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Structure Therapeutics has an average rating of “Moderate Buy” and an average target price of $107.90.

Structure Therapeutics Company Profile

Structure Therapeutics (NASDAQ:GPCR) is a clinical‐stage biotechnology company focused on the discovery and development of oral small‐molecule therapies that target G protein‐coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.